alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 21.1

                                 WORLDTEX, INC.
                                  Subsidiaries

--------------------------------------------------------------------------------

<TABLE>
<CAPTION>

                                                           State or Other
Name of Subsidiary                                 Jurisdiction of Incorporation
------------------                                 -----------------------------

<S>                                                          <C>
Filix Lastex S.A.                                            France

Galaurtex Sarl, S.A.                                         France

Moulinage de la Galaure                                      France

Worldtex France, S.A.                                        France

Willcox & Gibbs Filix of Delaware                            Delaware

Rubyco (1987), Inc.                                          Quebec

Regal Yarns of Argentina                                     North Carolina

Regal Manufacturing Company, Inc.                            Delaware

Fibrexa Ltda                                                 Colombia

Worldtex Colombiana I                                        Delaware

Worldtex Colombiana II                                       Delaware
</TABLE>
II 

109TH CONGRESS 

1ST SESSION S. 966 

To designate a United States courthouse located in Fresno, California, as 

the ‘‘Robert E. Coyle United States Courthouse’’. 

IN THE SENATE OF THE UNITED STATES 

APRIL 28, 2005 

Mrs. BOXER (for herself and Mrs. FEINSTEIN) introduced the following bill; 

which was read twice and referred to the Committee on Environment and 

Public Works 

A BILL 

To designate a United States courthouse located in Fresno, 

California, as the ‘‘Robert E. Coyle United States Courthouse’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. DESIGNATION. 

4 The United States courthouse bordered by O Street, 

5 P Street, Tulare Street, and Capitol Street in Fresno, 

6 California, shall be known and designated as the ‘‘Robert 

7 E. Coyle United States Courthouse’’. 
2 

•S 966 IS

1 SEC. 2. REFERENCES. 

2 Any reference in a law, map, regulation, document, 

3 paper, or other record of the United States to the United 

4 States courthouse referred to in section 1 shall be deemed 

5 to be a reference to the ‘‘Robert E. Coyle United States 

6 Courthouse’’. 

Æ
Exhibit 10(e)

THIRD AMENDMENT TO        HAGGAR CORP.        1992 LONG TERM INCENTIVE PLAN

1.Introduction. The Haggar Corp. 1992 Long Term Incentive Plan (as
amended, the "1992 Plan") was
initially approved and adopted by the stockholders of Haggar Corp., a Nevada corporation (the "Company"), on November 13, 1992. A First Amendment to Haggar Corp. 1992 Long Term Incentive Plan
was approved and adopted by the stockholders of the Company on February 24, 1994. A Second Amendment to Haggar Corp. 1992 Long Term Incentive Plan was approved and adopted by the stockholders
of the Company on February 5, 1995. Pursuant to Section 17, the 1992 Plan is hereby further amended as set forth herein.

2.Increase in Available Shares. For the purpose of increasing the maximum number of shares of the
Common Stock of the Company available for issuance under the 1992 Plan by 100,000 shares, Paragraph 5 of the 1992 Plan is amended by substituting the number "1,400,000" for the number
"1,300,000" in each place where the latter number occurs in said Paragraph 5.

3.Accelerated Vesting on Change In Control. For the purpose of accelerating the full vesting of
options and restricted shares granted under the 1992 Plan in the event of certain changes in control of the Company, the 1992 Plan is amended as follows:



1

---



4.Effect on Other Provisions. Except as expressly amended hereby, the 1992 Plan shall remain in full
force and effect as originally adopted and previously amended.

5.Adoption by Board. The foregoing amendments to the 1992 Plan were adopted by the Board of
Directors on February 10, 1999.

2

---

QuickLinks
Exhibit 32.1 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Gexa Corp. (the Company)
on Form 10-Q for the period ending September 30, 2004 (the Report), as filed
with the Securities and Exchange Commission on the date hereof, I, Neil
Leibman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that: 1. The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and 2. The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company. /s/ Neil
  LeibmanNeil LeibmanChief
  Executive OfficerDated:
  November 15, 2004 A signed original of this written statement required by Section 906 has
been provided to Gexa Corp. and will be retained by the Gexa Corp. and
furnished to the Securities and Exchange Commission or its staff upon request. 35
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Heart, Lung, and Blood Initial Review Group; Heart, Lung, and Blood Program Project Review Committee.                    

*Date:*                         June 18, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                         Jeffrey H. Hurst, PhD, Scientific Review Officer, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7208, Bethesda, MD 20892-7924, 301-435-0303,                         *hurstj@nhlbi.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: May 21, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-12583 Filed 5-28-09; 8:45 am]

BILLING CODE 4140-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Small Grants in Endoscopic Research.                    

*Date:*                         December 1, 2009.                    

*Time:*                         4 p.m. to 5:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).                    

*Contact Person:*                         Maria E. Davila-Bloom, Ph.D, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7637,                         *davila-bloomm@extra.niddk.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: October 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-25265 Filed 10-20-09; 8:45 am]

BILLING CODE 4140-01-P
<PAGE>



EXHIBIT 1.2 AMENDMENTS TO BYE-LAWS OF BRILLIANCE CHINA AUTOMOTIVE DATED JUNE 20,
2008

                               SPECIAL RESOLUTION
                                       OF
                  BRILLIANCE CHINA AUTOMOTIVE HOLDINGS LIMITED
                (Incorporated in Bermuda with limited liability)
                            PASSED ON 20TH JUNE, 2008

I, Wu Xiao An (also known as Ng Siu On), a director of Brilliance China
Automotive Holdings Limited (the "Company"), do hereby certify that at an annual
general meeting of the Company duly convened and held at Victoria Room IV, Level
2, Four Seasons Hotel Hong Kong, 8 Finance Street, Central, Hong Kong on Friday,
20th June, 2008 at 9.00 a.m., the following special resolution was duly passed:

          AS A SPECIAL RESOLUTION:

5.   "THAT the existing Bye-Laws of the Company be and are hereby amended in the
     following manner:

     (a)  by deleting the existing Bye-law 16 and substituting therefor the
          following new Bye-law 16:

          "16. Every certificate for shares, warrants or debentures or
               representing any other form of securities of the Company shall be
               issued under the Seal of the Company or under the Securities Seal
               or in such manner as the Board may authorize."

     (b)  by deleting the existing Bye-law 134(C) and substituting therefor the
          following new Bye-law 134(C):

          "(C) The Company may have a Securities Seal for use for sealing
               certificates for shares or other securities issued by the Company
               and no signature of any Director, officer or other person and no
               mechanical reproduction thereof shall be required on any such
               certificates or other document and any such certificates or other
               document to which such Securities Seal is affixed shall be valid
               and deemed to have been sealed and executed with the authority of
               the Board notwithstanding the absence of any such signature or
               mechanical reproduction as aforesaid. The Board may by resolution
               determine that the affixation of Securities Seal on certificates
               for shares or other securities issued by the Company be dispensed
               with or be affixed by printing the image of the Securities Seal
               on such certificates.""

Dated this 20th day of June, 2008


                                                       /s/ Wu Xiao An
                                                       -------------------------
                                                       WU Xiao An
                                                       (also known as Ng Siu On)
                                                       Director
**Exhibit 31.2**
**Sarbanes-Oxley Section 302 Certification**
I, Gino Chouinard, certify that:
1. I have reviewed this quarterly report on Form 10-Q of HearUSA, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement ofa material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements weremade, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financialinformation included in this l report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
 a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under oursupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made knownto us by others within those entities, particularly during theperiod in which this report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures,as of the end of the period covered by this report based on suchevaluations; and  c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of registrant’s board ofdirectors (or persons performing the equivalent function):
 a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reportingwhich are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financialinformation; and  b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internalcontrol over financial reporting.
Date: August 10, 2004
/s/Gino Chouinard
Eighteenth Amendment to Employment Agreement



 Exhibit 10.3(r) 
 EIGHTEENTH AMENDMENT TO EMPLOYMENT AGREEMENT 
 This Eighteenth Amendment to Employment Agreement is
made and entered into as of October 1, 2007, by and between PriceSmart, Inc., a Delaware Corporation (“Employer”) and Robert M. Gans (“Executive”). 
 Recitals 
  

	 	A)	On September 20, 1994 an Employment Agreement was made and entered into by and between Executive and Price Enterprises, Inc. 

  

	 	B)	Said Employment Agreement has been assigned to Employer and amended on seventeen prior occasions; 

  

	 	C)	Employer and Executive now desire to further amend the Employment Agreement, as set forth hereinbelow: 

 Agreement 
 1. Section 3.1 of the Employment Agreement, which currently
provides: 
 3.1    Term.    The term of Executive’s employment hereunder shall commence
on October 17, 1994 and shall continue until October 16, 2007 unless sooner terminated or extended as hereinafter provided (the “Employment Term”). 
 is hereby amended, to provide as follows: 
 3.1    Term.    The term of Executive’s employment hereunder shall commence on October 17, 1994 and shall continue until October 16, 2008 unless sooner terminated or extended as
hereinafter provided (the “Employment Term”). 
 2. All other terms of the Employment Agreement, as amended, shall remain unaltered
and fully effective. 
 Executed in San Diego, California, as of the date first written above. 
  

							
	EXECUTIVE	 		 	 EMPLOYER
  
 PRICESMART, INC.

				
	Robert M. Gans	 		 	By:	 	 
	 	 		 	Name:	 	Jose Luis Laparte
		 		 	Its:	 	President
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Securities and Exchange Commission

          - [File No. 500-1]

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Sun Sports and Entertainment, Inc. (“Sun Sports”) because of questions regarding the accuracy of statements by Sun Sports in press releases and statements to investors concerning, among other things, the company's business prospects and financial viability.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of Sun Sports.

                    Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the                           ( print page 54873)                        securities of the above-listed company is suspended for the period from 9:30 a.m. EDT October 21, 2009 through 11:59 p.m. EST, on November 3, 2009.                

By the Commission.

Florence E. Harmon,

Deputy Secretary.

[FR Doc. E9-25639 Filed 10-21-09; 11:15 am]

BILLING CODE 8011-01-P
Exhibit 32.1 CERTIFICATION
PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906OF THE
SARBANES-OXLEY ACT OF 2002 In connection with the
Quarterly Report of Gexa Corp. (the Company) on Form 10-Q for the
period ending June 30, 2004 (the Report), as filed with the
Securities and Exchange Commission on the date hereof, I, Neil Leibman, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1.         The Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended; and 2.         The information contained
in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.  /s/ Neil Leibman
Neil
LeibmanChief Executive OfficerDated: August 11, 2004 A signed original of this
written statement required by Section 906 has been provided to Gexa Corp. and
will be retained by the Gexa Corp. and furnished to the Securities and Exchange
Commission or its staff upon request.
EXHIBIT
32.2





CERTIFICATION


PURSUANT
TO 18 U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of QuantRx Biomedical Corporation (the
"Company") on Form 10-Q for the period ending March 31, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Sasha
Afanassiev, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002,
that to my knowledge:





1. The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.





/s/ Sasha AfanassievSasha
      AfanassievCFO,
      Treasurer & VP of Finance





Date:    May
15, 2009





A signed
original of this written statement required by Section 906 has been provided to
the Company and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.
EXHIBIT 32.1



                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                            AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the quarterly report of YoCream International, Inc.
(the Company) on Form 10-QSB for the period ended April 30, 2004 as filed with
the Securities and Exchange Commission on the date hereof (the Report), I, John
N. Hanna, Director, Chairman, and Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906
of the Sarbanes-Oxley Act of 2002, that:

       (1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

       (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.



/s/ John N. Hanna
-----------------
John N. Hanna
Chairman and Chief Executive Officer
YoCream International, Inc.

June 14, 2004


This certification is made solely for the purpose of 18 U.S.C. Section 1350,
and not for any other purpose.  A signed original of this written statement
required by Section 906 has been provided to YoCream International, Inc. and
will be retained by YoCream International, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.